Century Therapeutics Inc (IPSC) Stock Forecast & Price Target
Century Therapeutics Inc · NASDAQ
$2.08-0.03 (-1.42%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Century Therapeutics Inc, 3 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $2.00 to $8.00 (about 4.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $4.75 sits 128% above the current $2.08. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.12 next quarter toward $-0.46 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Moderate Buy
Strong Buy00%
Buy375%
Hold125%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Century Therapeutics Inc.
As of Jul, 3 of 4 firms rate IPSC a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IPSC EPS & revenue forecast
EPS · NEXT QUARTER
$-0.12
Range $-0.14 – $-0.11 · 3 analysts · -61% YoY
Next period, 3 analysts expect Century Therapeutics Inc to earn $-0.12 a share (range $-0.14 – $-0.11), versus $-0.32 a year earlier. Full-year consensus is $-0.46, growing to $-0.46 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Century Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IPSC.
#1
Michael Schmidt
Guggenheim · Rank #1
Buy
No targeton IPSC
Overall win rate
55%
+ Follow
#2
Geulah Livshits
Chardan Capital · Rank #100
Buy
$6.00+188.5% to target
Overall win rate
44%
+ Follow
#3
Mitchell Kapoor
HC Wainwright & Co. · Rank #165
Buy
$5.00+140.4% to target
Overall win rate
34%
+ Follow
#4
Edward Tenthoff
Piper Sandler · Rank #277
Buy
$4.00+92.3% to target
Overall win rate
29%
+ Follow
#5
Daina Graybosch
Leerink Partners
Hold
$2.00-3.8% to target
Coverage
—
+ Follow
IPSC stock forecast FAQ
What is IPSC's average 12-month price target?+
The 4 analysts with a live target average $4.75 for Century Therapeutics Inc over the next 12 months, ranging from a $8.00 high to a $2.00 low.
Is IPSC stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 4 analyst ratings, 3 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for IPSC?+
The Street-high target is $8.00 (Mizuho), and the Street-low is $2.00 (Leerink Partners). The average of all 4 active targets is $4.75.
How many Wall Street analysts cover IPSC?+
4 analysts have an active rating on Century Therapeutics Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering IPSC?+
Among analysts who currently cover IPSC, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #1). Their current call is Buy.
What is Century Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.12 per share (range $-0.14 – $-0.11) across 3 analysts. Full-year EPS is projected at $-0.46, rising to $-0.46 the following year.
How much revenue is Century Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading IPSC lately?+
As of Jul, 3 of 4 firms rate IPSC a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IPSC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
